STAGE III OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8
Clinical trials for STAGE III OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE III OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE III OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for head and neck cancer patients who Can't take standard chemo
Disease control Not yet recruitingThis study tests two different treatments for people with advanced head and neck cancer who cannot receive the standard drug cisplatin. Participants will get radiation therapy along with either the targeted drug cetuximab or a combination of two chemotherapy drugs, carboplatin an…
Matched conditions: STAGE III OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated May 15, 2026 10:42 UTC
-
New combo therapy aims to tame returning head and neck cancer
Disease control Not yet recruitingThis early-stage trial tests a drug called camonsertib combined with precise, high-dose radiation for people whose head and neck cancer has come back or cannot be removed by surgery. The study will include about 39 adults and aims to find the safest dose and see if the combinatio…
Matched conditions: STAGE III OROPHARYNGEAL (P16-NEGATIVE) CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:39 UTC